Altimmune, Inc. (ALT)

$14.03

+0.12 (+0.86%)
Rating:
Recommendation:
Neutral
Symbol ALT
Price $14.03
Beta 0.190
Volume Avg. 1.42M
Market Cap 689.702M
Shares () -
52 Week Range 3.83-23.49
1y Target Est -
DCF Unlevered ALT DCF ->
DCF Levered ALT LDCF ->
ROE 5.13% Neutral
ROA 4.46% Neutral
Operating Margin -
Debt / Equity 9.88% Neutral
P/E -
P/B 3.37 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest ALT news


Dr. Vipin Garg
Healthcare
Biotechnology
NASDAQ Global Market

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.